Selected Grants
BMT CTN 1902: Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomi
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2022 - 2027Long Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2021 - 2026A Phase I, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 as a single agent in relapsed or refractory hematological malignancies and in combgination with Daratumumab as a Salvage Regimen for Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Nektar Therapeutics · 2020 - 2025A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KARMMa-3)
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2019 - 2024An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Refractory/Relapsed Multiple Myeloma (KarMMa-7)
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2022 - 2023BMT CTN 1902: Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomi
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2022 - 2027Long Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2021 - 2026A Phase I, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 as a single agent in relapsed or refractory hematological malignancies and in combgination with Daratumumab as a Salvage Regimen for Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Nektar Therapeutics · 2020 - 2025A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KARMMa-3)
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2019 - 2024An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Refractory/Relapsed Multiple Myeloma (KarMMa-7)
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2022 - 2023A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd)
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2021 - 2023Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity in Subjects with Relapsed or Refractory Diffuse Large B-
Clinical TrialPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2019 - 2021Fellowships, Gifts, and Supported Research
KarMMa-3: a phase 3, multicenter, randomized, open-label study to compare the efficacy and safety of bb2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma ·
August 2019
Principal Investigator ·
Celgene
Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Prevention of CAR-T associated Neurotoxicity in Subjects with Relapsed or Refractory DLBCL receiving Axicabtagene Ciloleucel (Yescarta®) ·
2019
Principal Investigator ·
Jazz Pharmaceutical
External Relationships
- Janssen Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.